▶ ARGIRELINE · SUBTOPIC · DOSING LITERATURE

ARGIRELINE Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of ARGIRELINE. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for ARGIRELINE reports the following route(s) of administration: Topical (cosmetic). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of ARGIRELINE.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for ARGIRELINE of approximately n/a · topical · no systemic exposure. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of ARGIRELINE. Refer to the original publication for full protocol detail.

Blanes-Mira C, Clemente J, Jodas G, et al. (2002) reports the ARGIRELINE protocol used in A synthetic hexapeptide (Argireline) with antiwrinkle activity, published in Int J Cosmet Sci. PMID 18494888. See the source for the protocol-level dose range, frequency, and duration. link
Lupo MP, Cole AL (2007) reports the ARGIRELINE protocol used in Cosmeceutical peptides, published in Dermatol Ther. PMID 18045357. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ Argireline vs Botox · what's the difference?

Both target the SNARE complex but at different points. Botox (botulinum toxin) is an injected protease that cleaves SNAP-25 enzymatically, producing a strong and durable (3-4 month) effect at the neuromuscular junction. Argireline is a topical peptide that competitively inhibits SNAP-25 in the SNARE complex, producing a milder and shorter-duration effect without injection. Argireline does not replace Botox; it is a topical cosmetic complement.

▶ How long does Argireline take to work?

Published trials show measurable wrinkle-depth reduction at 28 days of twice-daily topical application. The effect is dose- and duration-dependent and reverses with cessation of application.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · Room temperature, light-protected

Reconstituted · n/a · supplied in cream/serum vehicle

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Cosmetic ingredient · not a drug. No FDA pharmaceutical approval required for topical cosmetic use.

WADA · Not listed on the WADA Prohibited List (cosmetic ingredient, no systemic exposure).

◀ ARGIRELINE OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-25